Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 6:38 PM ET


Company Overview of Noven Pharmaceuticals, Inc.

Company Overview

Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and estradiol transdermal system for the prevention of postmenopausal osteoporosis. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in ...

11960 SW 144th Street

Miami, FL 33186

United States

Founded in 1987

610 Employees





Key Executives for Noven Pharmaceuticals, Inc.

Chief Executive Officer
Chief Financial Officer, Vice President and Treasurer
Vice President of Operations
Chief Scientific Officer and Vice President
Age: 59
Chief Medical Officer and Executive Vice President of Product Development
Age: 60
Compensation as of Fiscal Year 2015.

Noven Pharmaceuticals, Inc. Key Developments

Noven Pharmaceuticals, Inc. Announces Management Changes

Noven Pharmaceuticals, Inc. announced that Jeff Mihm has been appointed as Noven’s Chief Executive Officer, succeeding Jeffrey Eisenberg. Mr. Mihm joined Noven in 2003 and since then has been consistently promoted to senior leadership positions of increasing scope and importance. Most recently, he served as Vice President, Chief Administrative Officer & General Counsel, where he oversaw Noven’s Business Development, Corporate Affairs, Human Resources, Information Technology and Legal/Compliance functions. Prior to Noven, he served as Senior Corporate Counsel to Panamerican Beverages, Inc., and previously was a partner with the law firm of Steel Hector & Davis (now part of Squire Patton Boggs). John Choi has been appointed as Vice President, Chief Financial Officer & Treasurer, succeeding Michael Price. Mr. Choi has served Noven since 2010, most recently as Noven’s Executive Director – Business Planning & Analysis. Prior to Noven, Mr. Choi served as Director of Commercial Operations & Planning for Ther-Rx (a branded pharmaceutical division of KV Pharmaceuticals). Michael Greene has been appointed as Vice President, General Counsel & Corporate Secretary, succeeding Jeff Mihm in those roles. Mr. Greene has served Noven since 2010, most recently as Noven’s Deputy General Counsel & Executive Director – Alliance Management. Prior to Noven, Mr. Greene was an attorney at the law firm of Paul, Hastings, Janofsky & Walker, where he specialized in mergers and acquisitions (M&A) and other complex corporate transactions, including pharmaceutical industry transactions.

Noven Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015

Noven Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Noven Pharmaceuticals, Inc. Replaces Andrew Panagy with Scott Briggs as Vice President, Marketing & Sales

Noven Pharmaceuticals, Inc. announced the appointment of Scott Briggs as the company’s new Vice President, Marketing & Sales, succeeding Andrew Panagy, who is retiring. In this role, reporting to Jeffrey Eisenberg, the company’s President and Chief Executive Officer, Briggs is responsible for all marketing and sales activities at Noven and Noven Therapeutics (the company’s specialty pharmaceutical business unit). Prior to this appointment, he served as Vice President Women’s Health Sales for Noven Therapeutics, and as Noven’s Executive Director, Marketing and Managed Markets.

Similar Private Companies By Industry

Company Name Region
GANIC Pharmaceuticals, Inc. United States
Xeris Pharmaceuticals, Inc. United States
Baxter Pharmaceutical Products, Inc. United States
Cavion LLC United States
Zuellig Botanicals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Noven Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at